Table 1 Clinical Characteristics of Patients with UC at Enrollment.
From: Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis
UC | MES 0/1 | MES 0/1 | MES 0/1 | p value | MES 2/3 | MES 2/3 | MES 2/3 | MES 2/3 | p value | |
|---|---|---|---|---|---|---|---|---|---|---|
Relapse | Non-relapse | Response | Refractory | Non-response | ||||||
Total: n = 51 | Total: n = 24 | n = 7 | n = 17 | Total: n = 27 | n = 6 | n = 13 | n = 8 | |||
Female/male | 24/27 | 11/13 | 6/1 | 5/12 | 1 | 13/14 | 1/5 | 8/5 | 4/4 | 0.23 |
Age, yr, median (IQR) | 45 (34–58) | 43.5 (37–56.8) | 42 (37.5–55) | 45 (38–56) | 0.9 | 46 (32–59) | 44.5 (40–49) | 39 (27–67) | 47.5 (35–56) | 0.99 |
Disease yr, median (IQR) | 6 (3–14) | 8 (3–16) | 5 (3–12.5) | 8.5 (2.8–16.3) | 0.79 | 5 (3–8.5) | 5.5 (4.25–7.5) | 4 (3–11) | 6 (4–10) | 0.87 |
Total Mayo score, median (IQR) | 3 (1–8) | 1 (0.75–2) | 1 (0.5–2) | 1 (1–2) | 0.74 | 8 (6–10) | 7 (6–9) | 8 (6–9) | 8.5 (6–10) | 0.75 |
Body mass index, median (IQR) | 20.3 (18–23) | 19.5(18–22) | 18.6 (17–19) | 21.0 (18–22) | 0.058 | 20.5 (18–25) | 20.5 (20–25) | 20.3 (18–25) | 21.1 (20–23) | 0.39 |
Type of disease | 1 | 0.093 | ||||||||
Proctitis | 5 (9.8%) | 3 (15%) | 1 | 2 | 2 (7%) | 1 | 0 | 0 | ||
Left-sided colitis | 17 (33.3%) | 7 (26%) | 2 | 5 | 10 (37%) | 4 | 4 | 2 | ||
Pancolitis | 27 (52.9%) | 12 (52%) | 4 | 8 | 15 (56%) | 1 | 9 | 6 | ||
Right-sided colitis | 2 (0.39%) | 2 (7%) | 0 | 2 | 0 (0%) | 0 | 0 | 0 | ||
Medication | ||||||||||
5ASA/SASP | 49 (96.1%) | 25 (93%) | 6 | 17 | 0.29 | 26 (96%) | 6 | 13 | 7 | 0.52 |
Corticosteroids | 10 (19.6%) | 0 (0%) | 0 | 0 | – | 10 (37%) | 1 | 5 | 4 | 0.45 |
AZA/6MP | 18 (35.3%) | 6 (22%) | 2 | 4 | 1 | 12 (44%) | 1 | 6 | 5 | 0.25 |
Apheresis | 0 (0%) | 0 (0%) | 0 | 0 | – | 0 (0%) | 0 | 0 | 0 | – |
Anti-TNFαtherapy | 10 (19.6%) | 4 (15%) | 1 | 1 | 0.51 | 6 (22%) | 0 | 3 | 3 | 0.34 |
Tacrolimus | 0 (0%) | 0 (0%) | 0 | 0 | – | 0 (0%) | 0 | 0 | 0 | – |
Duration of remission after enrollment, median (IQR) | 18 (16–24) | 72 (60–85) | ||||||||
